Pipeline Preview
Recent FDA action (through August 2012) related to, ferric carboxymaltose injection, Injectafer, abiraterone acetate, Zytiga, cabozantinib, Exelixis, eltrombopag, Promacta, AEZS-130 oral ghrelin agonist, inhaled nitric oxide, GeNO LLC, gevokizumab, XOMA, calcipotriene cream, Dovonex, montelukast sodium, Singulair, lidocaine topical patch 5%, Lidoderm, filgrastim, Neupogen
Complete response
■ Ferric carboxymaltose injection (Injectafer, Luitpold Pharmaceuticals) for the treatment of iron deficiency anemia. In the complete response letter (CRL) FDA said that its decision to withhold approval at this time was not related to any issues with the Injectafer NDA filing, but with Luitpold's manufacturing facility in Shirley, N.Y. During a recent inspection, issues in the manufacturing facility were noted by FDA inspectors. This is the same facility that is to be used to manufacture Injectafer for the US market. The company is working with FDA to resolve the issues found in FDA's recent inspection. Luitpold believes it has adequately responded to all the clinical questions concerning Injectafer raised by FDA during the current review period.
Priority review
■ Cabozantinib (Exelixis), a potent dual inhibitor of the MET and VEGF pathways designed to block MET-driven tumor escape, for the treatment of an advanced form of medullary thyroid cancer.
■ Eltrombopag (Promacta, Ligand Pharmaceuticals and GlaxoSmithKline) thrombopoeitin receptor agonist for the treatment of thrombocytopenia in patients with chronic hepatitis C virus infection.
■ AEZS-130 oral ghrelin agonist (Aeterna Zentaris) as a diagnostic test for adult growth hormone deficiency.
Orphan drug designations
■ Inhaled nitric oxide (GeNO LLC) (delivered via the GeNOsyl MVG-2000 delivery system) for the treatment of pesistent pulmonary hypertension in newborns.
■ Gevokizumab (XOMA) IL-1 beta modulating antibody for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.
First-time generic approvals
Calcipotriene cream (equiv to Dovonex)
SANDOZ
Montelukast sodium (equiv to Singulair) tablets
APOTEX, AUROBINDO PHARMA, ENDO PHARMACEUTICALS, GLENMARK GENERICS, KUDCO IRELAND, MYLAN, ROXANE LABORATORIES, SANDOZ, TEVA, AND TORRENT
Montelukast sodium (equiv to Singulair) chewable tablets
APOTEX, AUROBINDO, ENDO, KUDCO, MYLAN, ROXANE, SANDOZ, TEVA, AND TORRENT
Montelukast sodium (equiv to Singulair) oral granule form
TEVA
Lidocaine topical patch 5% (equiv to Lidoderm)
WATSON
Filgrastim (equiv to Neupogen)
TEVA
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
